Halda Raises $126m For First Clinical Trial Of Its RIPTAC Modality

Heterobifunctional Molecules From A PROTAC Pioneer

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Halda will take its first RIPTAC molecule into a clinical trial in prostate cancer, offering a new small molecule modality in an indication where patients and doctors prefer oral drugs.

Venture capital. Long term business investment
Halda has raised $202m to date • Source: Shutterstock

Induced proximity biology – bringing two molecules together to cause some kind of reaction – is in its heyday via the field of targeted protein degradation with proteolysis targeting chimera (PROTAC) therapeutics reaching previously undruggable targets. Now, Halda Therapeutics, with $126m in new venture capital financing, will conduct its first clinical trial of a novel induced proximity modality from a PROTAC pioneer.

Key Takeaways

  • Halda Therapeutics raised $126m to take its first RIPTAC, invented at the company and inspired by the research of PROTAC pioneer Craig Crews at Yale, into the clinic in 2025 in prostate cancer.

Halda founder and Yale University professor Craig Crews, founder of PROTAC developer Arvinas, Inc., wanted to inspire the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.

Scrip-Business (Free-1): Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Nabil

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Sponsored By

Nancy Tests SPARC-931 Part 8

This is a short description. This is a short description.

spo

Akash test for clone

Test article to check the clone issue

More from Business

How A New Healthcare Dialogue Is Driving Market Access In Mexico

Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.